The Matrix Reloaded: The Hepatic Matrisome as a Therapeutic Opportunity to Fight Liver Fibrosis
Biomolecules · 2026
DOI: 10.3390/biom16060884 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Cristina Benavides und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Farmacología, Facultad de Medicina, Universitat de València, 46010 Valencia, Spain. Hauptthemen laut MEDLINE: Liver Cirrhosis, Extracellular Matrix, Liver, Extracellular Matrix Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Generalitat Valenciana, Ministerio de Ciencia, Innovación y Universidades.
Abstract (Originalsprache)
Liver fibrosis is the excessive accumulation of extracellular matrix (ECM) that occurs in most types of chronic liver diseases (CLDs) as a response to sustained liver injury. While the ECM comprises different proteins, collagen being the most abundant, the term matrisome refers to a plethora of ECM-related molecules, including collagen-associated proteins, growth factors, cytokines, enzymes and their endogenous inhibitors. The hepatic matrisome undergoes significant qualitative and quantitative changes during liver fibrosis. Despite intense research over recent years, our understanding of the matrisome in the liver—both in health and disease—and particularly of its function beyond its conventional structural role, remains poor. This review highlights how comprehending hepatic matrisome responses to liver injury can yield novel insights into disease progression and regression and could be exploited as a potential antifibrotic strategy. The antifibrotic potency of drugs that interfere with the matrisome at different levels has been demonstrated in preclinical studies, but translation to clinical trials remains still limited. So far, simtuzumab (LOXL2 inhibitor antibody), imatinib (small-molecule inhibitor against discoidin domain receptors—DDRs), bexotegrast (integrin inhibitor), GR-MD-02 (galectin 3 inhibitor), and BMS-986263 (siRNA-targeting HSP47) have been or are being evaluated in clinical trials related to CLD, and some of them have shown promising results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Farmacología, Facultad de Medicina, Universitat de València, 46010 Valencia, Spain.
- FISABIO-Hospital Universitario Dr. Peset, 46017 Valencia, Spain.
- Departamento de Fisiología, Facultad de Medicina, Universitat de València, 46010 Valencia, Spain.
- CIBERehd (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, 46010 Valencia, Spain.
ORCID-Profile: Cristina Benavides, Fernando Solano, Olga Martínez-Arroyo, Juan V Esplugues, Ana Blas-García, Nadezda Apostolova
Förderung
- Instituto de Salud Carlos III
- Generalitat Valenciana
- Ministerio de Ciencia, Innovación y Universidades
- Spanish Ministry of Science, Innovation and Universities
- European Union
- Instituto de Salud Carlos III, Spanish Ministry of Science, Innovation and Universities
Zitieren
APA
Benavides, C., Kecheva, P., Solano, F., Martínez-Arroyo, O., Esplugues, J. V., Blas-García, A., & Apostolova, N. (2026). The Matrix Reloaded: The Hepatic Matrisome as a Therapeutic Opportunity to Fight Liver Fibrosis. Biomolecules. https://doi.org/10.3390/biom16060884
Vancouver
Benavides C, Kecheva P, Solano F, Martínez-Arroyo O, Esplugues JV, Blas-García A, et al. The Matrix Reloaded: The Hepatic Matrisome as a Therapeutic Opportunity to Fight Liver Fibrosis. Biomolecules. 2026. doi:10.3390/biom16060884
BibTeX
@article{Benavides2026,
author = {Benavides, Cristina and Kecheva, Pepa and Solano, Fernando and Martínez-Arroyo, Olga and Esplugues, Juan V and Blas-García, Ana and Apostolova, Nadezda},
title = {The Matrix Reloaded: The Hepatic Matrisome as a Therapeutic Opportunity to Fight Liver Fibrosis},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16060884}
}
EUVIMED